Medipost
Scope
Date
~
-
Bio & PharmaMedipost completes first dose of Cartistem in phase 3 clinical trials in Japan
South Korea's stem cell research company Medipost Co. said on Monday that it has completed the administration of Cartistem, a stem cell treatment fo...
Jan 17, 2023 (Gmt+09:00)
-
Bio & PharmaMedipost's Cartistem shows effects on patellar cartilage defect patients
Medipost's knee osteoarthritis treatment Cartistem has been mentioned in a renowned international journal, showing that it is effective even in pati...
Dec 27, 2022 (Gmt+09:00)
-
Bio & PharmaMedipost, OmniaBio to enhance cooperation for CDMO business
South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...
Dec 01, 2022 (Gmt+09:00)
-
Bio & PharmaMedipost to expand CDMO business with 10 new clean rooms in Korea
Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO)...
Oct 18, 2022 (Gmt+09:00)
-
Bio & PharmaMedipost acquires Canada’s OmniaBio for CDMO business
Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract devel...
May 31, 2022 (Gmt+09:00)
-
Korean startupsPrivate equity consortium buys 30% stake in biotech firm Medipost
South Korea’s first generation biotech firm Medipost Co. will sell a 30% stake to a private equity consortium, the company announced after W...
Mar 17, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
